Sirio Pharma Co., Ltd. (SHE:300791)
China · Delayed Price · Currency is CNY 17.11
-0.35 (-2.00%)
Aug 4, 2026, 3:04 PM CST
Sirio Pharma Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 5,253 | 7,912 | 6,167 | 6,293 | 6,637 | 7,513 | |
Market Cap Growth | -25.92% | 28.31% | -2.01% | -5.18% | -11.66% | -31.92% |
Enterprise Value | 6,305 | 9,109 | 7,186 | 7,062 | 6,079 | 7,014 |
Last Close Price | 17.11 | 25.66 | 19.67 | 19.29 | 20.24 | 22.58 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 44.38 | 57.95 | 18.97 | 22.39 | 31.26 | 32.41 |
Forward PE | 14.08 | 18.70 | 15.13 | 19.62 | 25.53 | 18.28 |
PS Ratio | 1.22 | 1.86 | 1.46 | 1.76 | 2.65 | 3.17 |
PB Ratio | 1.77 | 2.67 | 2.34 | 2.45 | 2.46 | 2.95 |
P/TBV Ratio | 2.51 | 3.85 | 3.95 | 4.42 | 2.81 | 3.38 |
P/FCF Ratio | 135.25 | 61.37 | 39.83 | - | 43.90 | - |
P/OCF Ratio | 10.68 | 13.88 | 10.88 | 16.30 | 14.92 | 22.01 |
PEG Ratio | - | 0.90 | 0.90 | 0.90 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.46 | 2.14 | 1.71 | 1.97 | 2.42 | 2.96 |
EV/EBITDA Ratio | 24.16 | 22.67 | 11.96 | 11.83 | 16.57 | 18.49 |
EV/EBIT Ratio | 28.78 | 43.38 | 18.11 | 18.77 | 25.06 | 24.95 |
EV/FCF Ratio | 162.33 | 70.65 | 46.41 | - | 40.21 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.61 | 0.57 | 0.61 | 0.53 | 0.35 | 0.34 |
Debt / EBITDA Ratio | 6.93 | 3.79 | 2.53 | 2.16 | 2.50 | 2.27 |
Debt / FCF Ratio | 46.59 | 13.06 | 10.38 | - | 6.20 | - |
Net Debt / Equity Ratio | 0.35 | 0.33 | 0.31 | 0.24 | -0.28 | -0.15 |
Net Debt / EBITDA Ratio | - | 2.45 | 1.38 | 1.03 | -2.05 | -0.98 |
Net Debt / FCF Ratio | 26.85 | 7.64 | 5.36 | -9.36 | -4.98 | 2.03 |
Asset Turnover | 0.76 | 0.77 | 0.79 | 0.76 | 0.63 | 0.73 |
Inventory Turnover | 6.11 | 6.48 | 6.01 | 7.00 | 7.36 | 6.34 |
Quick Ratio | 1.36 | 1.32 | 1.82 | 1.88 | 4.62 | 4.88 |
Current Ratio | 1.85 | 1.81 | 2.45 | 2.57 | 5.18 | 5.76 |
Return on Equity (ROE) | 0.21% | 0.73% | 10.83% | 9.12% | 8.09% | 9.81% |
Return on Assets (ROA) | 2.42% | 2.37% | 4.64% | 5.01% | 3.79% | 5.43% |
Return on Invested Capital (ROIC) | 5.51% | 5.66% | 10.63% | 12.90% | 9.94% | 12.54% |
Return on Capital Employed (ROCE) | 4.70% | 4.60% | 8.50% | 8.50% | 6.50% | 8.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.24% | 1.73% | 5.27% | 4.47% | 3.20% | 3.09% |
FCF Yield | 0.74% | 1.63% | 2.51% | -1.04% | 2.28% | -2.44% |
Dividend Yield | 0.74% | 0.51% | 2.54% | 3.37% | 1.02% | 1.05% |
Payout Ratio | 154.60% | 134.05% | 67.56% | 29.83% | 35.84% | 31.29% |
Buyback Yield / Dilution | -0.77% | -0.63% | 0.36% | 0.82% | 4.47% | -5.00% |
Total Shareholder Return | -0.02% | -0.13% | 2.90% | 4.19% | 5.49% | -3.95% |